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Background and objective: Entecavir (ETV) is a standard of care for chronic hepatitis B 
(CHB). In a bioequivalence study, ETV from Dong-A ST (Baracle®) was found to have a phar-
macokinetic profile equivalent to ETV from Bristol-Myers Squibb (BMS) (Baraclude®). The 
present study was conducted to evaluate the antiviral activity and safety of ETV from Dong-A 
ST in comparison to ETV from BMS in patients with CHB.
Methods: In this multicenter, double-blind, active-controlled, stratified-randomized, parallel 
group, comparative trial, 118 treatment-naïve patients with CHB were randomly assigned to 
receive either 0.5 mg of ETV from Dong-A ST or ETV from BMS once daily for 48 weeks. 
The primary efficacy endpoint was virologic improvement (a mean reduction from baseline in 
serum HBV DNA levels) at 24 weeks. Secondary efficacy endpoints included a mean reduc-
tion in serum HBV DNA levels at 48 weeks, proportion of patients with undetectable levels 
of serum HBV DNA, rates of hepatitis B e antigen (HBeAg) loss and seroconversion, rates 
of HBsAg loss and seroconversion, and rates of normalization of alanine aminotransferase 
(ALT) levels.
Results: From baseline to week 24, HBV DNA levels (log
10
) decreased by 4.81 and 4.63 
with ETV from Dong-A ST and with ETV from BMS, respectively. The upper limit of two-
sided 95% confidence intervals (CI) (equivalent to one-sided 97.5% CIs) for the difference 
between the treatment groups was 0.208, which was below the noninferiority margin of 1, 
thus supporting the noninferiority of ETV from Dong-A ST in comparison to ETV from 
BMS. No statistically significant differences were noted between the treatment groups in 
all secondary and tertiary efficacy endpoints. Safety profiles were also similar between the 
two groups.
Conclusion: In patients with previously untreated HBeAg-positive or negative HBV infection, 
the efficacy of ETV from Dong-A ST was noninferior to that of ETV from BMS, and there were 
no significant differences in efficacy or safety between two groups.
Keywords: chronic hepatitis B, generic, ETV from Dong-A ST (Baracle®)
Introduction
Hepatitis B is a chronic liver disease caused by hepatotrophic hepatitis B virus (HBV) 
infection. Approximately 2 billion people worldwide are exposed to HBV and more 
than 350 million people are chronically infected therewith.1 HBV is also a major cause 
of cirrhosis and hepatocellular carcinoma (HCC). The prevalence of HBV infection 
worldwide differs among geographic areas, and proportions of carriers vary from 0.1% 
to 15%. In Korea, HBV infections have gradually decreased since commercialization of 
the hepatitis B vaccine (1990s), although 3.7% of the population is still infected.2–4
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The goal of chronic hepatitis B (CHB) treatment is to 
suppress the proliferation of HBV. By inhibiting HBV prolif-
eration, inflammation is relieved, and fibrosis, cirrhosis, liver 
failure, or HCC can be prevented. Thereby, it is possible to 
reduce mortality due to liver disease and to improve the sur-
vival rate thereof.5 Although the ideal treatment goal is loss 
of hepatitis B surface antigen (HBsAg), complete treatment of 
HBV is almost impossible, because nuclear covalently closed 
circular DNA (cccDNA) remains after treatment. In clinical 
practice, alanine aminotransferase (ALT) normalization, 
nondetection of serum HBV DNA, serum hepatitis B e 
antigen (HBeAg) loss or seroconversion, and histologic 
improvement are used as treatment response indicators.6
Entecavir (ETV) is a deoxyguanosine nucleoside analog 
that is converted to its active form, ETV-triphosphate, in vivo. 
ETV-triphosphate exerts antiviral effects by inhibiting three 
steps of replication: priming of HBV DNA polymerase, 
reverse transcription of the HBV DNA negative strand 
from pregenomic mRNA, and synthesis of the HBV DNA 
positive strand.7,8
In a Phase III clinical trial, ETV was shown to be superior 
to lamivudine in terms of histologic improvement, reduction 
of HBV DNA levels from baseline, proportion of patients with 
undetectable HBV DNA, and ALT normalization.9,10 ETV 
is now widely used as a standard therapeutic agent for CHB 
and is recommended as a first-line treatment by international 
and domestic guidelines, including the American Association 
for the Study of Liver Diseases (AASLD), European Asso-
ciation for the Study of the Liver (EASL), Asian Pacific 
Association for the Study of the Liver (APASL), and Korean 
Association for the Study of the Liver (KASL).6,11,12
Baracle® is a ETV product developed by Dong-A ST 
based on a pharmacokinetic profile equivalent to ETV from 
BMS in bioequivalence tests. However, studies have yet to 
demonstrate the efficacy and safety of ETV from Dong-A 
ST in comparison with ETV from BMS for CHB patients. 
Therefore, the current study was designed to compare the 
antiviral efficacy and safety between ETV from Dong-A 
ST (Baracle) and ETV from BMS (Baraclude®) in patients 
with CHB.
Patients and methods
study design
This study was conducted as a multicenter, double-blind, 
active-controlled, randomized with stratification, parallel 
group, and comparative trial at 18 sites in South Korea 
from September 2013 to November 2015. As patients with 
HBeAg positivity or negativity may differ in their responses 
to antiviral therapy, a stratified randomization was performed 
to ensure balance between treatment groups.
All subjects who consented to participate in the present 
trial provided written informed consent and were subjected 
to screening tests. Within 4 weeks after screening, subjects 
who were determined to be eligible for the study were ran-
domized with stratification 1:1 to Baracle (ETV 0.5 mg; 
Dong-A ST Co., Seoul, Republic of Korea) or Baraclude 
(ETV 0.5 mg; Bristol-Myers Squibb Korea) treatment groups 
based on HBeAg status (positive/negative). After stratified 
randomization, subjects were administered either ETV from 
Dong-A ST or ETV from BMS via one tablet once daily on an 
empty stomach (2 hours after taking meal or at least 2 hours 
before taking meal). Each subject took the investigational 
products (IP) for 48 weeks, during which the subjects visited 
the clinical trial institution according to the schedule speci-
fied in the study protocol, to receive the planned efficacy and 
safety assessments.
Patients
Inclusion criteria were male and female patients of ages 
18–65 years who were diagnosed as HBsAg-positive 
at the screening visit and had a medical record of CHB 
for at least 6 months. For those who were diagnosed as 
HBeAg-positive at the screening visit, HBV DNA levels 
were $1×105 copies/mL, which was quantified through 
real-time PCR, and for those who were diagnosed as HBeAg-
negative, HBV DNA levels were $1×104 copies/mL. Subjects 
were to have ALT levels between 2 times and 10 times the 
upper limit of the normal (ULN) levels at the screening visit. 
Subjects with compensated cirrhosis were eligible for the 
study if their ALT levels were between the ULN and 10 times 
the ULN levels. Subjects were not administered any antiviral 
agents, including interferon or pegylated interferon agents, for 
at least 12 weeks and within 24 weeks prior to screening.
Exclusion criteria included infection with hepatitis C virus 
(HCV), hepatitis D virus (HDV), human immunodeficiency 
virus (HIV), decompensated diseases, hematochromatosis, 
Wilson’s disease, alcoholic liver disease, autoimmune liver 
disease, and α-1 antitrypsin deficiency. Subjects who were 
administered immunosuppressive agents or systemic corti-
costeroids for more than 4 weeks within 24 weeks prior to 
screening were excluded. Subjects with less than 50 mL/min 
of creatinine clearance (body weight and age were adjusted by 
the Cockgraft–Gault method) at the screening visit or subjects 
with greater than 50 mL/min of α-fetoprotein at the screening 
visit, who were presumed to have HCC based on the result 
of the relevant imaging test, were also excluded.
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study assessments
Efficacy
The primary efficacy endpoint was virologic improvement, 
defined as a change in HBV DNA level (log
10
) from baseline 
to week 24 after IP administration.
Secondary efficacy endpoints included virologic end-
points (the proportion of subjects whose HBV DNA levels 
were less than 300 copies/mL at week 24 and week 48, 
change in HBV DNA levels [log
10
] from baseline to week 48), 
biochemical endpoints (the proportion of subjects whose 
ALT levels become normal at week 24 and week 48, the 
proportion of subjects whose HBV DNA levels were less 
than 300 copies/mL and whose ALT levels became normal 
at week 48), and serologic endpoints (the proportion of 
subjects who were HBeAg-positive at the screening visit, 
but lost HBeAg at week 24 and week 48; the proportion of 
subjects who were HBeAg-positive at the screening visit, 
but showed HBeAg seroconversion at week 24 and week 48; 
the proportion of subjects who showed loss of HBsAg and 
emergence of anti-HBs at week 48).
The tertiary efficacy endpoint was the proportion of 
subjects who expressed HBV DNA gene mutations after 
IP administration, which was confirmed by HBV DNA 
sequencing.
safety
Adverse events, such as subjective and objective symptoms, 
and abnormalities in clinical laboratory tests and vital signs, 
were assessed. The number and percentage of subjects who 
experienced ALT flare ($10X ULN and $2X baseline) 
were also assessed.
statistical analysis
All efficacy analyses were performed on the full analysis 
set (FAS) and per-protocol set (PPS). The FAS population 
included all randomized subjects who received at least one 
dose of the study drug and had at least one valid post-baseline 
efficacy evaluation. The PPS population was defined as 
a subset of the FAS population who completed the study 
without any major protocol violations.
Assuming a one-sided α level of 0.025 and 80% power, a 
sample size of 92 patients was estimated with a noninferiority 
margin of 1. Considering a 20% drop-out rate, the study 
required a total of 116 patients. For the primary efficacy 
endpoint, the noninferiority of ETV from Dong-A ST to 
ETV from BMS was to be supported if the upper limit of 
the two-sided 95% CI (equivalent to one-sided 97.5% CI) 
was below the prespecified noninferiority margin of 1.9,10,13,14 
Other secondary and tertiary efficacy endpoints were com-
pared between the two treatment groups using Cochran–
Mantel–Haenszel test adjusted for a stratification factor, 
HBeAg (positive/negative), respectively. Differences in the 
HBV DNA levels (log
10
) from baseline to week 48 between 
the two treatment groups were analyzed using ANCOVA 
with HBeAg (positive/negative) as a stratification factor.
The number (N) and proportion (%) of subjects who lost 
HBeAg at week 24 and week 48 were compared between the 
two treatment groups using χ2 test or Fisher’s exact test.
The difference between the two groups with respect to the 
incidences of adverse events (AEs), adverse drug reactions 
(ADRs), serious adverse events (SAEs), and serious adverse 
drug reactions (SADRs) was analyzed using χ2 test of Fisher’s 
exact test. The number (N) and proportion (%) of subjects with 
ALT flare ($10X ULN and $2X baseline) were compared 
using χ2 test or Fisher’s exact test to determine if there was a 
statistically significant difference between the two groups.
All statistical analyses were performed using SAS version 
9.4 (SAS Institute Inc., Cary, NC, USA).
ethics statement
The study was approved by the Institutional Review Boards 
of each of the 18 participating institutions, including Asan 
Medical Center (IRB approval number: 2013-0660), The 
Catholic University of Korea Seoul St Mary’s Hospital 
(KC13MSMV0402), Gachon University Gil medical Center 
(GAIRB2013-170), Keimyung University Dongsan Medical 
Center (DSMC2013-06-034), Konkuk University Medical 
Center (KUH1010498), Kyungpook National University 
Hospital (KNUH2013-06-025), Korea University Guro Hos-
pital (KUGH13089), Dong-A University Hospital (13-090), 
Samsung Medical Center (SMC2013-06-059), Seoul 
National University Hospital (H-1306-079-498), Severance 
Hospital Yonsei University (4-2013-0333), Ulsan University 
Hospital (UUH2013-07-061), Inje University Busan Paik 
Hospital (13-100), Chonbuk National University Hospital 
(CUH2013-06-024), Chungnam National University Hospi-
tal (CNUH2013-06-007), Kosin University Gospel Hospital 
(KUGH2014-02-018), Presbyterian Medical Center (2014-06-
026), and Hanyang University Medical Center (HYUH2014-
05-024). The study was performed in compliance with good 
clinical practices, according to ICH guidelines.
Results
Baseline characteristics
The mean age of the included patients was 45.8±11.0 years, 
and male sex was predominant (67.8%). The mean prevalent 
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period of CHB was 11.4±10.8 years, and all patients were 
treatment-naïve. Forty-seven (39.8%) patients had com-
pensated cirrhosis, and the rate of HBeAg positivity was 
59.3%. HBV genotype was C in all patients. There was no 
significant difference in the baseline characteristics between 
the ETV from Dong-A ST and ETV from BMS treatment 
groups (Table 1).
comparison of hBV Dna declines at 
weeks 24 and 48
Serum HBV DNA levels declined equally at 24 and 
48 weeks in both groups. Using the full analysis set, at 
week 24, the declines in HBV DNA levels from baseline 
were 4.79 log
10
 in ETV from Dong-A ST and 4.64 log
10
 in 
ETV from BMS group. In ANCOVA analysis with HBeAg 
as a covariate, which was also a stratification factor, HBV 
DNA declines from baseline to week 24 were 4.81 log
10
 in 
ETV from Dong-A ST and 4.63 log
10
 in ETV from BMS 
group. Regarding the differences in HBV decline, the upper 
limit of two-sided 95% CI (ie, 97.5% one-sided CI) was 
0.208, which is less than the noninferiority margin of 1. 
At week 48, the covariate analysis with HBeAg as a covariate 
also revealed that HBV DNA decline was not significantly 
different between the two groups (P=0.6440): 5.0 log
10
 in 
ETV from Dong-A ST and 4.9 log
10
 in ETV from BMS 
group (Table 2).
Proportion of patients with hBV Dna 
levels ,300 copies/ml at week 48
Figure 1 shows the mean decreases of serum HBV DNA 
levels during the study period in patients who received 
either ETV from Dong-A ST or ETV from BMS. There 
was no significant difference in HBV decline between the 
two groups during the entire study period. At week 24, 36 
(66.7%) patients in ETV from Dong-A ST and 31 (50.0%) 
in ETV from BMS group achieved HBV DNA less than 
300 copies/mL. At week 48, 44 (81.5%) patients in the 
ETV from Dong-A ST group and 44 (71.0%) in the ETV 
from BMS group achieved HBV DNA levels less than 
300 copies/mL. After adjustment of HBeAg status, we 
found no significant difference in the proportion of patients 
with HBV DNA ,300 copies/mL at both weeks 24 and 48 
(respectively, P=0.0530 and P=0.2128) (Figure 2).
alT normalization and hBeag loss
For all included patients, the rates of ALT normalization 
were 79.6% in the ETV from Dong-A ST group and 74.2% 
in the 3 ETV from BMS group at week 24, which was not 
statistically different (P=0.5131). At week 48, the rates were 
77.8% in the ETV from Dong-A ST group and 77.4% in the 
ETV from BMS group (P=0.9851) (Figure 3). Regarding 
HBeAg loss during antiviral therapy, 3 (10.0%) patients 
in the ETV from Dong-A ST group and 3 (8.3%) patients 
with HBeAg-positive in the ETV from BMS group showed 
HBeAg loss at week 24. No other patients achieved HBeAg 
loss or seroconversion thereafter (Figure 4).
adverse events
All adverse events were presented after standardization into 
system organ classes (SOC) and preferred terms (PT) using 
MedDRA (Version 16.0) (Table 3). There was a total of 47 
adverse events (AE; Any untoward medical occurrence in 
a patient or clinical investigation subject administered a 
pharmaceutical product, which does not necessarily have 
a causal relationship with this treatment) from 24 (43.6%) 
patients in the ETV from Dong-A ST group and 73 AEs 
from 31 (50.0%) patients in the ETV from BMS group 
(P=0.4912). Mild, moderate, and severe AEs occurred in 
37, 8, and 2 cases in the ETV from Dong-A ST group and 
in 62, 9, and 2 cases in the ETV from BMS group. Adverse 
drug reactions (ADRs; All noxious and unintended responses 
to a medicinal product related to any dose) were observed in 
one case in the ETV from Dong-A ST group and two cases 
(from 1 patient) in the ETV from BMS group. There were 
Table 1 Baseline characteristics of the patients included in comparison study
Variables ETV from Dong-A ST ETV from BMS Total P-value
number of patients 55 63 118 –
Prevalent period of chB (years)a 11.3±10.7 11.4±11.1 11.4±10.8 0.9849
Previous antiviral therapy (%) 0 (0) 0 (0) 0 (0) –
compensated cirrhosis (%) 24 (43.6) 23 (36.5) 47 (39.8) 0.4301
hBeag-positive (%) 32 (58.2) 38 (60.3) 70 (59.3) 0.8138
anti-hBe positive (%) 30 (54.5) 29 (46.0) 59 (50.0) 0.3562
hBV genotype c (%) 55 (100) 63 (100) 118 (100) –
Note: aFrom year of the first diagnosis to year of screening for this study.
Abbreviations: BMs, Bristol-Myers squibb; chB, chronic hepatitis B; eTV, entecavir; hBV, hepatitis B virus; hBeag, hepatitis B e antigen.
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four cases of serious AEs (SAEs; AE which results in death, 
life-threatening conditions, inpatient hospitalization, pro-
longation of existing hospitalization, persistent/significant 
disability/incapacity, or a congenital anomaly/birth defect) 
seen in three patients (5.5% and 4.8%) in each of the ETV 
from Dong-A ST and ETV from BMS groups. There was 
no serious ADR (SADR; ADR which results in death, 
life-threatening condition, inpatient hospitalization, pro-
longation of existing hospitalization, persistent/significant 
disability/incapacity, or a congenital anomaly/birth defect) 
in either group.
Discussion
CHB imposes a significant global health care burden; approx-
imately 5% of individuals throughout the world are estimated 
to be infected with HBV, and the annual mortality associ-
ated with persistent HBV infection is about 1.2 million.15 
International guidelines recommend ETV together with 
tenofovir (TDF) as the first-line therapy in the treatment of 
naïve CHB patients because of its potent antiviral activity 
and higher genetic barrier.9,10,12 Continuous suppression of 
HBV replication is clinically important as the risk of cirrhosis 
and/or HCC in CHB patients increases proportionally with 
increases in serum HBV DNA concentrations.16,17 Indeed, 
since the introduction of ETV in clinical practice, there have 
been many studies showing the long-term clinical benefits 
of ETV in terms of prevention of CHB progression (ie, cir-
rhosis or HCC).18,19
In the current study, we observed no differences in sup-
pression of HBV replication and safety between those taking 
ETV from Dong-A ST and ETV from BMS. The change in 
HBV DNA levels (log
10
) from baseline to week 24, which 
was the primary endpoint of study, was 4.81 log
10
 in ETV 
from Dong-A ST and 4.63 log
10
 in ETV from BMS group, 
confirming that ETV from Dong-A ST is not inferior to ETV 
Table 2 comparison of hBV Dna declines at weeks 24 and 48
Parameters ETV from 
Dong-A ST
ETV from BMS Differencea ETV from 
Dong-A ST
ETV from BMS Differencea
Full analysis 
set
n=54 n=62 Full analysis 
set
n=54 n=62
Mean ± SD, 
Median, Min, Max
95% 2-sided 
CIb
Mean ± SD, 
Median, Min, Max
P-value
Baseline (week 
0)
7.36±1.34,
7.24, 4.22, 9.00
7.47±1.36,
7.43, 3.88, 9.00
Baseline 
(week 0)
7.36±1.34
7.24, 4.22, 9.00
7.47±1.36,
7.43, 3.88, 9.00
Week 24 2.57±0.83,
2.16, 2.06, 5.76
2.83±1.03,
2.48, 2.06, 6.16
Week 48 2.39±0.75,
2.06, 2.06, 5.76
2.55±0.92,
2.06, 2.06, 6.16
change from 
baseline at 
week 24
-4.79±1.26,
-4.8, -6.93, -0.94
-4.64±1.05,
-4.84, -6.55, -1.81
change from 
baseline at 
week 48
-4.97±1.35,
-5.02, -6.93, -0.94
-4.92±1.21,
-5.06, -6.93, -1.81
P-valuec ,0.0001 ,0.0001 P-valuec ,0.0001 ,0.0001
ls (mean ± se) -4.81±0.14 -4.63±0.13 (-0.571, 0.208) ls mean ± se -5.00±0.15 -4.90±0.14 0.6440
Notes: aeTV from Dong-a sT – eTV from BMs. banalysis of covariance (ancOVa). cPaired t-test.
Abbreviations: BMs, Bristol-Myers squibb; eTV, entecavir; hBV, hepatitis B virus; ls, logarithmic scale; se, standard error.
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from BMS. At week 48, declines in HBV DNA were also not 
significantly different between the two groups (P=0.6440): 
5.0 log
10
 in the ETV from Dong-A ST and 4.9 log
10
 in the 
ETV from BMS group. The proportions of patients with 
HBV DNA ,300 copies/mL at weeks 24 and 48 were also 
not different between the two groups (66.7% vs 50.0% at 
week 24, 81.5% vs 71.0% at week 48). Thus, the overall 
antiviral activity was deemed to be comparable between 
ETV from Dong-A ST and ETV from BMS. In particular, the 
rates of undetectable serum HBV DNA levels in the present 
study were similar with ETV pivotal clinical trials, wherein 
the rates were 67% in HBeAg-positive patients and 90% in 
HBeAg-negative patients.9,10
Because of relatively short treatment period of 1 year, 
the rates of HBeAg loss might not be fully evaluated or 
compared in HBeAg-positive patients. Nonetheless, the 
HBeAg loss rates at week 48 were not different between two 
groups: 9.7% in ETV from Dong-A ST and 8.3% in ETV 
from BMS group.
A major concern regarding generic antiviral agent for 
HBV infection would be whether it can show bioequivalence, 
comparable efficacy, and safety in real patients. First, ETV 
from Dong-A ST demonstrated an equivalent pharmacoki-
netic profile to ETV from BMS in bioequivalence tests. When 
ETV from Dong-A ST or ETV from BMS 0.5 mg Tab was 
administered in 36 healthy male adults, the two-sided 90% 
CI of C
max
 and AUC
t
 were 1.0366–1.1740 and 0.9605–1.1149, 
respectively. Thus, it was confirmed that they were within the 
acceptable bioequivalence range of 0.80–1.25. Second, in this 
multicenter, prospective randomized trial, antiviral potency 
indicated by serum HBV DNA declines at weeks 24 (primary 
endpoint) and 48 (secondary endpoint) and the proportions 
of patients with HBV DNA ,300 copies/mL (secondary 
endpoint) were not different between the two drugs. Lastly, 
there was a similar safety profile in the ETV from Dong-A 
ST and ETV from BMS groups. Most of adverse events were 
mild, and there were rare ADRs or SAEs. In addition, there 
was no case of SADR. In particular, ETV is known not to be 
related to nephrotoxicity or loss of bone density. In our study, 
both ETV from Dong-A ST and from BMS did not result 
in elevation of serum creatinine or decrease of glomerular 
filtration rate (GFR) during study period (data not shown).
Although regulation authority does not request a manu-
facturer to conduct clinical trials to approve a generic drug, 
data comparing efficacy and safety between generic and 
branded drugs are sometimes necessary. This is because, 
in a survey, 25% of physicians stated that they would only 
increase prescribing generic drugs if additional clinical trials 
were presented.20
This study has a strength in that efficacy and safety were 
compared between original and generic anti-HBV drugs by 
a well-designed randomized trial. This is the first report to 
show the comparable efficacy and safety of generic anti-HBV 
drug. A limitation of this study is a relative short (1 year) 
duration of drug administration, which may not allow for 
the comparison of long-term virologic and/or biochemical 
responses between the two drugs.
Conclusion
In conclusion, we demonstrated that ETV from Dong-A ST 
is not inferior to ETV from BMS in treatment-naïve HBeAg 
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Figure 3 The rates of alT normalization at weeks 24 and 48. 
Note: There is no significant difference in the rates between the ETV from Dong-A 
sT and eTV from BMs groups.
Abbreviations: alT, alanine transaminoferase; BMs, Bristol-Myers squibb; eTV, 
entecavir; hBV, hepatitis B virus.
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Figure 4 The rates of hBeag loss during antiviral therapy.
Abbreviations: BMs, Bristol-Myers squibb; eTV, entecavir; hBeag, hepatitis B e 
antigen.
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rates of HBeAg seroconversion, ALT normalization, and 
efficacy profile.
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